Skip to main content
Erschienen in: American Journal of Cardiovascular Drugs 1/2016

01.02.2016 | Current Opinion

Medication Adherence Following Acute Coronary Syndrome: Does One Size Fit All?

verfasst von: Daniel D. L. Bernal, Luke R. E. Bereznicki, Leanne Chalmers, Ronald L. Castelino, Angus Thompson, Patricia M. Davidson, Gregory M. Peterson

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Guideline-based management of acute coronary syndrome (ACS) is well established, yet some may challenge that strict implementation of guideline recommendations can limit the individualization of therapy. The use of all recommended medications following ACS places a high burden of responsibility and cost on patients, particularly when these medications have not been previously prescribed. Without close attention to avoiding non-adherence to these medications, the full benefits of the guideline recommendations will not be realized in many patients. Using a case example, we discuss how the recognition of adherence barriers can be an effective and efficient process for identifying patients at risk of non-adherence following ACS. For those identified as at risk, the World Health Organization’s model of adherence barriers is explored as a potentially useful tool to assist with individualization of therapy and promotion of adherence.
Literatur
1.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50(7):652–726.CrossRef Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50(7):652–726.CrossRef
2.
Zurück zum Zitat Cooper A, Skinner J, Nherera L, Feder G, Ritchie G, Kathoria M, Turnbull N, Shaw G, MacDermott K, Minhas R, Packham C, Squires H, Thomson D, Timmis A, Walsh J, Williams H, White A. Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2007. Cooper A, Skinner J, Nherera L, Feder G, Ritchie G, Kathoria M, Turnbull N, Shaw G, MacDermott K, Minhas R, Packham C, Squires H, Thomson D, Timmis A, Walsh J, Williams H, White A. Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2007.
3.
Zurück zum Zitat Acute Coronary Syndromes Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust. 2006;184(8 Suppl):S9–29. Acute Coronary Syndromes Guidelines Working Group. Guidelines for the management of acute coronary syndromes 2006. Med J Aust. 2006;184(8 Suppl):S9–29.
4.
Zurück zum Zitat Sabaté E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003. Sabaté E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
5.
Zurück zum Zitat AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens. 2012;14(12):877–86.CrossRef AlGhurair SA, Hughes CA, Simpson SH, Guirguis LM. A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the World Health Organization multidimensional adherence model. J Clin Hypertens. 2012;14(12):877–86.CrossRef
6.
Zurück zum Zitat Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J Clin Psychiatry. 2008;69(1):74–80.PubMedCrossRef Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J Clin Psychiatry. 2008;69(1):74–80.PubMedCrossRef
7.
Zurück zum Zitat Svarstad BL, Kotchen JM, Shireman TI, et al. The team education and adherence monitoring (TEAM) trial: pharmacy interventions to improve hypertension control in blacks. Circ Cardiovasc Qual Outcomes. 2009;2(3):264–71.PubMedPubMedCentralCrossRef Svarstad BL, Kotchen JM, Shireman TI, et al. The team education and adherence monitoring (TEAM) trial: pharmacy interventions to improve hypertension control in blacks. Circ Cardiovasc Qual Outcomes. 2009;2(3):264–71.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.PubMedCrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.PubMedCrossRef
9.
Zurück zum Zitat George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369–76.PubMedCrossRef George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369–76.PubMedCrossRef
10.
Zurück zum Zitat Ingersoll K, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.PubMedPubMedCentralCrossRef Ingersoll K, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213–24.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.PubMed Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171(9):814–22.PubMed
12.
Zurück zum Zitat Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.PubMedCrossRef Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.PubMedCrossRef
13.
Zurück zum Zitat Choudhry NK, Bykov K, Shrank WH, et al. Eliminating medication copayments reduces disparities in cardiovascular care. Health Aff (Millwood). 2014;33(5):863–70.CrossRef Choudhry NK, Bykov K, Shrank WH, et al. Eliminating medication copayments reduces disparities in cardiovascular care. Health Aff (Millwood). 2014;33(5):863–70.CrossRef
14.
Zurück zum Zitat Peterson GM, Thompson A, Pulver LK, et al. Management of acute coronary syndromes at hospital discharge: do targeted educational interventions improve practice quality? J Healthc Qual. 2012;34(1):26–34.PubMedCrossRef Peterson GM, Thompson A, Pulver LK, et al. Management of acute coronary syndromes at hospital discharge: do targeted educational interventions improve practice quality? J Healthc Qual. 2012;34(1):26–34.PubMedCrossRef
15.
Zurück zum Zitat Dhalla IA, O’Brien T, Morra D, et al. Effect of a postdischarge virtual ward on readmission or death for high-risk patients: a randomized clinical trial. JAMA. 2014;312(13):1305–12.PubMedCrossRef Dhalla IA, O’Brien T, Morra D, et al. Effect of a postdischarge virtual ward on readmission or death for high-risk patients: a randomized clinical trial. JAMA. 2014;312(13):1305–12.PubMedCrossRef
16.
Zurück zum Zitat Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012.PubMed Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012.PubMed
17.
Zurück zum Zitat Sullivan MD, LaCroix AZ, Russo J, Katon WJ. Self-efficacy and self-reported functional status in coronary heart disease: a six-month prospective study. Psychosom Med. 1998;60(4):473–8.PubMedCrossRef Sullivan MD, LaCroix AZ, Russo J, Katon WJ. Self-efficacy and self-reported functional status in coronary heart disease: a six-month prospective study. Psychosom Med. 1998;60(4):473–8.PubMedCrossRef
18.
Zurück zum Zitat Chew DP, French J, Briffa TG, et al. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. Med J Aust. 2013;199(3):185–91.PubMedCrossRef Chew DP, French J, Briffa TG, et al. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. Med J Aust. 2013;199(3):185–91.PubMedCrossRef
19.
Zurück zum Zitat Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.PubMedCrossRef Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.PubMedCrossRef
20.
Zurück zum Zitat Chew DP, Huynh LT, Liew D, Astley C, Soman A, Brieger D. Potential survival gains in the treatment of myocardial infarction. Heart. 2009;95(22):1844–50.PubMedCrossRef Chew DP, Huynh LT, Liew D, Astley C, Soman A, Brieger D. Potential survival gains in the treatment of myocardial infarction. Heart. 2009;95(22):1844–50.PubMedCrossRef
21.
Zurück zum Zitat Huynh LT, Chew DP, Sladek RM, Phillips PA, Brieger DB, Zeitz CJ. Unperceived treatment gaps in acute coronary syndromes. Int J Clin Pract. 2009;63(10):1456–64.PubMedCrossRef Huynh LT, Chew DP, Sladek RM, Phillips PA, Brieger DB, Zeitz CJ. Unperceived treatment gaps in acute coronary syndromes. Int J Clin Pract. 2009;63(10):1456–64.PubMedCrossRef
22.
Zurück zum Zitat Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109(6):745–9.PubMedCrossRef Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109(6):745–9.PubMedCrossRef
23.
Zurück zum Zitat Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am. Heart J. 2007;154(6):1108–15.PubMedCrossRef Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am. Heart J. 2007;154(6):1108–15.PubMedCrossRef
24.
Zurück zum Zitat Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.PubMedPubMedCentralCrossRef Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Belleli E, Naccarella L, Pirotta M. Communication at the interface between hospitals and primary care: a general practice audit of hospital discharge summaries. Aust Fam Physician. 2013;42:886–90.PubMed Belleli E, Naccarella L, Pirotta M. Communication at the interface between hospitals and primary care: a general practice audit of hospital discharge summaries. Aust Fam Physician. 2013;42:886–90.PubMed
26.
Zurück zum Zitat Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One. 2013;8(5):e61735.PubMedPubMedCentralCrossRef Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One. 2013;8(5):e61735.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol. 2011;11(1):149.PubMedPubMedCentralCrossRef Garfield S, Clifford S, Eliasson L, Barber N, Willson A. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol. 2011;11(1):149.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003). 2011;51(1):90–4.CrossRef Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003). 2011;51(1):90–4.CrossRef
29.
Zurück zum Zitat Guenette L, Moisan J, Preville M, Boyer R. Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records. J Clin Epidemiol. 2005;58(9):924–33.PubMedCrossRef Guenette L, Moisan J, Preville M, Boyer R. Measures of adherence based on self-report exhibited poor agreement with those based on pharmacy records. J Clin Epidemiol. 2005;58(9):924–33.PubMedCrossRef
30.
Zurück zum Zitat Bailey SC, Oramasionwu CU, Wolf MS. Rethinking adherence: a health literacy-informed model of medication self-management. J Health Commun. 2013;18:20–30.PubMedPubMedCentralCrossRef Bailey SC, Oramasionwu CU, Wolf MS. Rethinking adherence: a health literacy-informed model of medication self-management. J Health Commun. 2013;18:20–30.PubMedPubMedCentralCrossRef
32.
33.
Zurück zum Zitat Redberg RF. Medication regimen adherence and patient outcomes. JAMA Intern Med. 2014;174(2):193-193. Redberg RF. Medication regimen adherence and patient outcomes. JAMA Intern Med. 2014;174(2):193-193.
34.
Zurück zum Zitat Jin H, Tang C, Wei Q, et al. Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge. BMC Cardiovasc Disord. 2014;14:127.PubMedPubMedCentralCrossRef Jin H, Tang C, Wei Q, et al. Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge. BMC Cardiovasc Disord. 2014;14:127.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Mathews R, Wang TY, Honeycutt E, et al. Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015;170(1):62–9.PubMedCrossRef Mathews R, Wang TY, Honeycutt E, et al. Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015;170(1):62–9.PubMedCrossRef
36.
Zurück zum Zitat Puspitasari HP, Aslani P, Krass I. Pharmacists’ and consumers’ viewpoints on counselling on prescription medicines in Australian community pharmacies. Int J Pharm Pract. 2010;18(4):202–8.PubMedCrossRef Puspitasari HP, Aslani P, Krass I. Pharmacists’ and consumers’ viewpoints on counselling on prescription medicines in Australian community pharmacies. Int J Pharm Pract. 2010;18(4):202–8.PubMedCrossRef
37.
Zurück zum Zitat López-Sendó J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341–62.CrossRef López-Sendó J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341–62.CrossRef
39.
Zurück zum Zitat Jiang X, Sit JW, Wong TKS. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: evidence from Chengdu, China. J Clin Nurs. 2007;16(10):1886–97.PubMedCrossRef Jiang X, Sit JW, Wong TKS. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: evidence from Chengdu, China. J Clin Nurs. 2007;16(10):1886–97.PubMedCrossRef
44.
Zurück zum Zitat Redfern J, Briffa T, Ellis E, Freedman SB. Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial. Heart. 2009;95(6):468–75.PubMedCrossRef Redfern J, Briffa T, Ellis E, Freedman SB. Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial. Heart. 2009;95(6):468–75.PubMedCrossRef
45.
Zurück zum Zitat Sangster J, Furber S, Allman-Farinelli M, et al. A population-based lifestyle intervention to promote healthy weight and physical activity in people with cardiac disease: the PANACHE (Physical Activity, Nutrition And Cardiac HEalth) study protocol. BMC Cardiovascular Disorders. 2010;10:17.PubMedPubMedCentralCrossRef Sangster J, Furber S, Allman-Farinelli M, et al. A population-based lifestyle intervention to promote healthy weight and physical activity in people with cardiac disease: the PANACHE (Physical Activity, Nutrition And Cardiac HEalth) study protocol. BMC Cardiovascular Disorders. 2010;10:17.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Varnfield M, Karunanithi M. Information and communication technology-based cardiac rehabilitation homecare programs. Smart Homecare Technol Telehealth. 2015;3:69–9. Varnfield M, Karunanithi M. Information and communication technology-based cardiac rehabilitation homecare programs. Smart Homecare Technol Telehealth. 2015;3:69–9.
47.
Zurück zum Zitat Davidson PM, Macdonald PS. Interventions for modern times: complex, collaborative, and culturally appropriate. Circ Cardiovasc Qual Outcomes. 2011;4(6):584–6.PubMedCrossRef Davidson PM, Macdonald PS. Interventions for modern times: complex, collaborative, and culturally appropriate. Circ Cardiovasc Qual Outcomes. 2011;4(6):584–6.PubMedCrossRef
48.
Zurück zum Zitat Sandesara PB, Lambert CT, Gordon NF, et al. Cardiac Rehabilitation and Risk Reduction: time to “Rebrand and Reinvigorate”. J Am Coll Cardiol. 2015;65(4):389–95.PubMedCrossRef Sandesara PB, Lambert CT, Gordon NF, et al. Cardiac Rehabilitation and Risk Reduction: time to “Rebrand and Reinvigorate”. J Am Coll Cardiol. 2015;65(4):389–95.PubMedCrossRef
49.
Zurück zum Zitat Jalal ZS, Smith F, Taylor D, Patel H, Finlay K, Antoniou S. Pharmacy care and adherence to primary and secondary prevention cardiovascular medication: a systematic review of studies. Eur J Hosp Pharm. 2014;21(4):238–44.CrossRef Jalal ZS, Smith F, Taylor D, Patel H, Finlay K, Antoniou S. Pharmacy care and adherence to primary and secondary prevention cardiovascular medication: a systematic review of studies. Eur J Hosp Pharm. 2014;21(4):238–44.CrossRef
50.
Zurück zum Zitat Bernal DL, Bereznicki LE, Peterson GM. Improving medication adherence and helping patients make lifestyle changes. JAMA Intern Med. 2014;174(10):1707–8.PubMedCrossRef Bernal DL, Bereznicki LE, Peterson GM. Improving medication adherence and helping patients make lifestyle changes. JAMA Intern Med. 2014;174(10):1707–8.PubMedCrossRef
51.
Zurück zum Zitat Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076–82.PubMedCrossRef Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076–82.PubMedCrossRef
52.
Zurück zum Zitat Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. Cardiol: J Am Coll; 2014. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project. Cardiol: J Am Coll; 2014.
53.
Zurück zum Zitat Hugtenburg JG, Timmers L, Elders PJM, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Preference Adherence. 2013;7:675–82.PubMedPubMedCentralCrossRef Hugtenburg JG, Timmers L, Elders PJM, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Preference Adherence. 2013;7:675–82.PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Ho P, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2013;174(2):1–8. Ho P, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2013;174(2):1–8.
55.
Zurück zum Zitat Davidson PM, Abbott P, Davison J, DiGiacomo M. Improving medication uptake in Aboriginal and Torres Strait Islander peoples. Heart Lung Circ. 2010;19(5–6):372–7.PubMedCrossRef Davidson PM, Abbott P, Davison J, DiGiacomo M. Improving medication uptake in Aboriginal and Torres Strait Islander peoples. Heart Lung Circ. 2010;19(5–6):372–7.PubMedCrossRef
56.
57.
Zurück zum Zitat Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.PubMedCrossRef Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.PubMedCrossRef
58.
Zurück zum Zitat de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase z of the a to z trial. JAMA. 2004;292(11):1307–16.PubMedCrossRef de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase z of the a to z trial. JAMA. 2004;292(11):1307–16.PubMedCrossRef
59.
Zurück zum Zitat Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT–TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy–thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol. 54(25):2358–2362. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes: from the PROVE IT–TIMI 22 (pravastatin or atorvastatin evaluation and infection therapy–thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol. 54(25):2358–2362.
60.
Zurück zum Zitat Ozasa N, Morimoto T, Bao B, et al. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol. 2013;168(2):774–9.PubMedCrossRef Ozasa N, Morimoto T, Bao B, et al. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol. 2013;168(2):774–9.PubMedCrossRef
61.
Zurück zum Zitat Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344–426.PubMedCrossRef Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344–426.PubMedCrossRef
62.
Zurück zum Zitat Gislason GH, Rasmussen JN, Abildstrøm SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–8.PubMedCrossRef Gislason GH, Rasmussen JN, Abildstrøm SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–8.PubMedCrossRef
63.
Zurück zum Zitat Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149(3):444–50.PubMedCrossRef Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149(3):444–50.PubMedCrossRef
64.
Zurück zum Zitat Garcia B, Småbrekke L, Trovik T, Giverhaug T. Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(3):703–9.PubMedCrossRef Garcia B, Småbrekke L, Trovik T, Giverhaug T. Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. Eur J Clin Pharmacol. 2013;69(3):703–9.PubMedCrossRef
65.
Zurück zum Zitat Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86.PubMedCrossRef Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86.PubMedCrossRef
66.
Zurück zum Zitat Kocas C, Abaci O, Oktay V, et al. Percutaneous coronary intervention vs. optimal medical therapy—the other side of the coin: medication adherence. J Clin Pharm Ther. 2013;38(6):476–9.PubMedCrossRef Kocas C, Abaci O, Oktay V, et al. Percutaneous coronary intervention vs. optimal medical therapy—the other side of the coin: medication adherence. J Clin Pharm Ther. 2013;38(6):476–9.PubMedCrossRef
67.
Zurück zum Zitat Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.PubMedCrossRef Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.PubMedCrossRef
Metadaten
Titel
Medication Adherence Following Acute Coronary Syndrome: Does One Size Fit All?
verfasst von
Daniel D. L. Bernal
Luke R. E. Bereznicki
Leanne Chalmers
Ronald L. Castelino
Angus Thompson
Patricia M. Davidson
Gregory M. Peterson
Publikationsdatum
01.02.2016
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 1/2016
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-015-0149-9

Weitere Artikel der Ausgabe 1/2016

American Journal of Cardiovascular Drugs 1/2016 Zur Ausgabe

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.